Concepedia

Fathima Zumla Cader

FZ

Statistics

Publications

7

Citations

1.1K

H-Index

7

Active since

2012

Affiliations

Brigham and Women's Hospital(Current)

Harvard University

Dana-Farber Cancer Institute

University of Birmingham

University of Washington

Fathima Zumla Cader is an author at Brigham and Women's Hospital specializing in immunotherapy, immunology, and medicine.

ORCID

Top concepts

Publications per year

2012–2020

7

Publications

7

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma

Margaretha G.M. Roemer, Robert Redd, Fathima Zumla Cader et al. · Journal of Clinical Oncology · 2018 · 353 citations

, , +22

Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell–rich and exhausted T-effector microenvironment

Fathima Zumla Cader, Ron C.J. Schackmann, Xihao Hu et al. · Blood · 2018 · 160 citations · Full text

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors

Robert E. White, Patrick C. Rämer, Kikkeri N. Naresh et al. · Journal of Clinical Investigation · 2012 · 159 citations

, , +25

Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion

Kirsty Wienand, Bjoern Chapuy, Chip Stewart et al. · Blood Advances · 2019 · 155 citations · Full text

A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma

Fathima Zumla Cader, Xihao Hu, Walter L. Goh et al. · Nature Medicine · 2020 · 134 citations · Full text

, , +12

1–5 of 7